Physician profile
Rubens Chang
NPI 1659635159
$1,627.64
in general payments reported to CMS, 2019-2025
17 companies · $676 in 2025
The $676 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $266 · 2021: $11.60 · 2022: $53.93 · 2023: $70.87 · 2024: $549 · 2025: $676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,296.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $262.40 | 2024-2025 | Opdivo |
| Janssen Biotech, INC. | $211.60 | 2024-2025 | Darzalex, Tecvayli, Carvykti |
| Dendreon Pharmaceuticals LLC | $211.52 | 2024-2025 | Provenge |
| Bayer Healthcare Pharmaceuticals INC. | $142.83 | 2024 | |
| Pfizer INC. | $142.69 | 2022-2025 | |
| Eisai INC. | $140.43 | 2024 | |
| Galvanize Therapeutics, INC | $130.43 | 2025 | Aliya System |
| Rigel Pharmaceuticals, INC. | $114.61 | 2019 | |
| Merck Sharp & Dohme LLC | $78.12 | 2019 | |
| Exelixis INC. | $73.20 | 2019 | |
| Astellas Pharma US INC | $70.87 | 2023 | |
| Adc Therapeutics America, INC. | $22.13 | 2022 | |
| Boston Scientific Corporation | $15.21 | 2025 | Watchman Flx |
| Janssen Pharmaceuticals, INC | $11.60 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rubens Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.